Back to top
more

HealthEquity (HQY)

(Real Time Quote from BATS)

$92.98 USD

92.98
66,625

+1.14 (1.24%)

Updated Aug 8, 2025 10:52 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (97 out of 244)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

HealthEquity (HQY) Beats on Q4 Earnings, Margins Rise

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, alongside recording robust performances in all its segments, in the fourth quarter of fiscal 2023.

Zacks Equity Research

HealthEquity (HQY) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

HealthEquity (HQY) delivered earnings and revenue surprises of 8.82% and 1.92%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

HealthEquity (HQY) Surges 10.0%: Is This an Indication of Further Gains?

by Zacks Equity Research

HealthEquity (HQY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

HealthEquity (HQY) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

HealthEquity (HQY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Cano Health, Inc. (CANO) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Cano Health, Inc. (CANO) delivered earnings and revenue surprises of 280% and 3.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Retain HealthEquity (HQY) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.

Zacks Equity Research

Humana (HUM) Subsidiary Wins $70.8B DoD East Region Contract

by Zacks Equity Research

The latest award marks Humana's (HUM) military subsidiary's sixth TRICARE contract win.

Zacks Equity Research

Here's Why You Should Retain Inari Medical (NARI) Stock Now

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.

Zacks Equity Research

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Zacks Equity Research

Here's Why You Should Bet on ShockWave Medical (SWAV) Stock

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Zacks Equity Research

Are Medical Stocks Lagging Gilead Sciences (GILD) This Year?

by Zacks Equity Research

Here is how Gilead Sciences (GILD) and HealthEquity (HQY) have performed compared to their sector so far this year.

Zacks Equity Research

Here's What You Should Know From Centene's (CNC) 2023 Outlook

by Zacks Equity Research

Centene's (CNC) board boosts its share buyback program with a new $2-billion fund.

Zacks Equity Research

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research

Investors are optimistic about Patterson Companies (PDCO) on the back of its strong product line.

Zacks Equity Research

Stryker's (SYK) Citrefix to Boost Foot and Ankle Surgeries

by Zacks Equity Research

Stryker's (SYK) newly-launched Citrefix will help customers avoid chronic inflammation using Citregen. Its pull-out strength is greatly increased compared to other suture anchors.

Zacks Equity Research

Zacks Industry Outlook Highlights Medpace, HealthEquity and Progyny

by Zacks Equity Research

Medpace, HealthEquity and Progyny have been highlighted in this Industry Outlook article.

Urmimala Biswas headshot

3 Medical Services Stocks to Buy Amid Industry Challenges

by Urmimala Biswas

The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, HQY and PGNY are set to gain the most. However, staffing shortages may disrupt the trend.

Zacks Equity Research

How Much Upside is Left in HealthEquity (HQY)? Wall Street Analysts Think 30%

by Zacks Equity Research

The mean of analysts' price targets for HealthEquity (HQY) points to a 29.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.

Zacks Equity Research

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

Zacks Equity Research

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vinci Surgical System. Improving margins buoy optimism.

Zacks Equity Research

HealthEquity (HQY) Stock Falls 1.6% Despite Q3 Earnings Beat

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs besides recording robust performances in all its segments in the third quarter of fiscal 2023.

Zacks Equity Research

HealthEquity (HQY) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

HealthEquity (HQY) delivered earnings and revenue surprises of 8.57% and 4.60%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Gilead Sciences (GILD) and HealthEquity (HQY) have performed compared to their sector so far this year.

Zacks Equity Research

PINC vs. HQY: Which Stock Is the Better Value Option?

by Zacks Equity Research

PINC vs. HQY: Which Stock Is the Better Value Option?

Zacks Equity Research

Harpoon Therapeutics, Inc. (HARP) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 41.67% and 73.11%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?